Infant Bacterial Therapeutics
Staffan has over 20 years of experience in the pharmaceutical industry. Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca. Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.
Infant Bacterial Therapeutics
IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.